Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs VICI Properties Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while VICI Properties Inc trades at $26.16 (market cap $29.48B). The key difference: VICI Properties Inc is far larger — about 6.6× ACADIA Pharmaceuticals Inc.'s market cap, and VICI Properties Inc pays a 6.72% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | VICI | |
|---|---|---|
Market Cap | $4.49B | $29.48B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $33.93 |
52-Week Low | $20.06 | $26.09 |
Enterprise Value | $3.69B | $46.70B |
Dividend Yield | — | 6.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VICI Properties trades at $26.70, down 1.78% on the day, reflecting a bearish technical trend. The stock shows strong fundamentals with a P/E of 9.14, a net income margin of 76.83%, and consistent earnings beats in recent quarters. Recent news highlights its investment-grade balance sheet and a 6.8% dividend yield, though technical indicators signal caution with a bearish moving average consensus.
The outlook for VICI is positive based on fundamentals, with a consensus price target of $30.67 implying 15% upside. Risks include tenant concentration and market volatility, but the company's stable cash flows and analyst buy ratings (76.9%) support a favorable long-term view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
